UK-based Beringea has backed Disposable Cubicle Curtains Limited, trading as All in One Medical. DCCL manufactures and distributes an evolving range of patented, best in class, disposable curtains and blinds which actively destroy deadly and harmful pathogens.
Beringea, the growth capital investor that manages the Proven Venture Capital Trusts, announces that it has invested £3 million in Disposable Cubicle Curtains Limited (DCCL), trading as All in One Medical.
DCCL manufactures and distributes an evolving range of patented, best in class, disposable curtains and blinds which actively destroy deadly and harmful pathogens. Distributed to medical institutions, DCCL’s products are manufactured and shipped from its manufacturing plant in Wolverhampton, UK. Part of Beringea’s investment was used by DCCL to acquire the anti-microbial biocide manufacturer Fantex UK Limited. Fantex is developing biodegradable biocides, with an exceptionally fast kill rate, for a number of applications outside of the healthcare industry including the retail sector, and are in negotiations with several high street retailers.
Beringea Partner, Stephane Mery, who led the transaction commented: “I am thrilled with our investment, and to be supporting such a great team. I am also delighted that our investment is helping a British company bring its manufacturing back to the UK. DCCL’s highly specialised plant in Wolverhampton allows the Company to successfully outperform Chinese manufacturers on both quality and price. ”
Hospital Acquired Infections that cross infect patients, their carers and visitors to hospitals have become a global public health issue. A typical fabric cubicle curtain that surrounds a hospital bed has a high probability of having developed on its surface pathogens such as MRSA, ECOLI, VRE, or CDIFF. As a result, in certain A&E wards, curtains must be changed and cleaned up to 20x per annum. The replacement of traditional linen products with disposable, anti-microbial curtains, assists medical institutions in preventing and combating the outbreak of infectious diseases amongst patients, staff and visitors.
Demand for infection preventative medical products is also being driven by the increasing imposition of financial penalties by governments on hospitals that fail to meet minimum standards of hygiene and whose cross infection rates are deemed unacceptable.
John Hawkins, Chairman and CEO of All in One commented: “The disposable curtain market is rapidly growing here in the UK and abroad, and with the investment by Beringea, we are in a position to achieve global market leadership. The acquisition of Fantex allows us to provide a broad spectrum of highly effective pathogen and bacteria eliminating products, applicable across a wide variety of applications, for example keeping fabrics fresh, clean and odourless.”
For media enquiries please contact Beringea, T: +44 (0) 20 7845 7820
Notes to Editors
Beringea is an international growth capital firm with offices in London and Michigan, U.S.A, which invests in high growth companies. Beringea’s London office manages a number of funds, including the ProVen VCTs.
Beringea is a generalist investor with sector expertise in Media, Healthcare and Retail. Beringea‘s previous investments have included Fjordnet, Espresso Education, Saffron Digital and Mergermarket.
Beringea LLP is authorised and regulated by the Financial Conduct Authority.
About the ProVen VCTs
The ProVen VCTs (ProVen VCT, ProVen Growth & Income VCT and ProVen Planned Exit VCT) are funds raised under the government’s Venture Capital Trust scheme for supporting UK SMEs with equity investment. The original Ordinary share issues of ProVen VCT and ProVen Growth & Income VCT have generated higher Total Returns to investors than any other VCT share issues in their respective launch years, according to www.taxefficientreview.com.